MTNB · Matinas Biopharma Holdings Inc
United States · RS rating 99 · As of 2026-10-14
| Price | 2.48 USD |
|---|---|
| 1-day change | -0.8% |
| RS rating (overall / 1M / 3M / 12M) | 99 / 99 / 98 / 84 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 39 / 57 / 62 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +30.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +17.6% |
| Market cap (USD) | $4.0M |